CURE Expert Connections® is a video series designed to help patients and their loved ones along their cancer care journey by offering information and expert advice from leaders in oncology care. Expert medical professionals share their knowledge and insights on an array of topics to allow for a better understanding of what to expect following a cancer diagnosis. Expert Connections hopes to bridge the gap between patients and oncology professionals to ensure no question is left unanswered.
CLL: Treatment and Management Strategies for Best Outcomes
April 10th 2024Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, provide comprehensive insights on the diagnosis and treatment of chronic lymphocytic leukemia, highlighting decision-making practices, clinical trial data, and treatment outcome optimization.
Read More
Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life
November 28th 2023Christine Cooper, RN, BSN, and Aaron Gerds, MD, MS,discuss optimizing outcomes and quality-of-life in patients with myelofibrosis, the current treatment options and promising advances, and side-effect management.
Read More
Updates in Diagnosis, Treatment, and Management of Metastatic Uveal Melanoma
August 10th 2022Sunandana Chandra, MD, MS, delves into the evolution of the metastatic uveal melanoma treatment landscape and the discussions she has with patients during treatment decision-making.
Editor's note: Tebentafusp is pronounced “teh-BEN-tah-fuhsp.”
Read More
Triple-Negative Breast Cancer: Latasha’s Story
June 15th 2021A survivor of triple-negative breast cancer, Latasha Jordan, and an expert breast oncologist, Aditya Bardia, MD, MPH, provide key insights into the patient experience in triple-negative breast cancer and highlight the role of clinical trials in the current treatment landscape.
Read More
The Role of Tumor Infiltrating Lymphocyte (TIL) Therapy in NSCLC
May 11th 2021An expert in thoracic oncology, Adam J. Schoenfeld, MD, provides key insight into the use of cell therapy in non-small cell lung cancer after first-line treatment and highlights the potential for tumor-infiltrating lymphocyte (TIL) therapy depending on results from ongoing clinical trials.
Read More